1. Disease Information

Overview. Peroxisome biogenesis disorder 4B (PBD4B) is an autosomal recessive peroxisomal biogenesis disorder caused by biallelic (or, rarely, a specific monoallelic allelic-expression-imbalance mechanism — see §4) pathogenic variants in PEX6. It sits within the Zellweger spectrum disorder (ZSD) continuum — a single phenotypic spectrum historically split into three named entities (Zellweger syndrome > neonatal adrenoleukodystrophy [NALD] > infantile Refsum disease [IRD], severe→mild) that are now understood to reflect residual peroxisomal function rather than distinct diseases (GeneReviews, NBK1448). PEX6 defects are the second most common cause of ZSD after PEX1, accounting for roughly 10–14.5% of ZSD cases (GeneReviews, NBK1448; Ebberink et al. 2010, PMID:19877282). PEX6-caused ZSD spans an unusually wide severity range — from classic lethal neonatal Zellweger syndrome (PBD4A, OMIM:614862) through NALD/IRD-type PBD4B, to an ataxia–deafness–blindness (SCAR3/SCABD) presentation recognized in later childhood/adulthood, to the mildest end, Heimler syndrome 2 (hearing loss + amelogenesis imperfecta ± mild/late retinal disease, OMIM:616617).

Key identifiers: | Resource | ID | |---|---| | OMIM (phenotype, milder/NALD-IRD end) | #614863 PEROXISOME BIOGENESIS DISORDER 4B; PBD4B | | OMIM (phenotype, classic Zellweger end, same gene) | #614862 PBD4A | | OMIM (gene) | *601498 PEX6 | | OMIM (mildest allelic end) | #616617 Heimler syndrome 2 (HMLR2) | | MONDO | MONDO:0013931 | | Orphanet (gene page) | ORPHA PEX6 gene entry; component disorders NALD ORPHA:44, Infantile Refsum disease ORPHA:772, Zellweger syndrome ORPHA:912, umbrella "Peroxisome biogenesis disorder, Zellweger syndrome spectrum" ORPHA:79189 | | MeSH | Zellweger Syndrome (D015211) | | ICD-11 | 5C56.0 Zellweger spectrum | | HGNC | PEX6, HGNC:8858 |

Synonyms: PBD4B; NALD (PEX6-caused); IRD/Infantile Refsum disease (PEX6-caused); SCAR3; SCABD; Autosomal recessive spinocerebellar ataxia-blindness-hearing loss syndrome; Autosomal recessive cerebellar ataxia-blindness-deafness syndrome (Monarch Initiative MONDO:0013931).

Evidence basis of this report: predominantly aggregated disease-level resources (OMIM, GeneReviews consensus chapter, Orphanet, systematic mutation surveys of 75–77 PEX6 patients) supplemented by individual case reports/small case series (Mixteco founder cluster n=3; late-onset PEX6 case n=1; French-Canadian founder cohort) rather than large single-cohort EHR data — consistent with an ultra-rare monogenic disease.

2. Etiology

Disease causal factor: Exclusively genetic/mechanistic — biallelic (or the specific monoallelic AEI mechanism, see §4) pathogenic loss-of-function or hypomorphic variants in PEX6 (6p21.1), encoding an AAA-ATPase peroxin required for peroxisomal matrix-protein import. There is no known environmental, infectious, or acquired cause; PBD4B is a Mendelian disorder in the strict sense.

Genetic risk factors: - Biallelic PEX6 pathogenic variants (missense, nonsense, frameshift, splice-site, large deletion) — causal. - The specific c.2578C>T (p.Arg860Trp) variant acting in the heterozygous state when in cis with a 3′UTR polyadenylation-site variant (rs144286892, c.442_445delTAAA) that causes allelic expression imbalance (AEI), effectively producing dominant-like disease from one overexpressed hypomorphic allele (Falkenberg et al. 2017, AJHG, PMC/ResearchGate; identified in 7 unrelated ZSD patients + 1 affected half-sibling). - Population-specific founder alleles increase local risk: a French-Canadian PEX6 founder mutation raising ZSD incidence in the Saguenay–Lac-Saint-Jean region of Quebec toward ~1/12,000 (vs. ~1/50,000 general North American incidence) (PMC3483250); a Mixteco-population founder variant c.1409G>C (p.Gly470Ala)* identified in 2/3 related neonatal cases from Central California (Slaton et al. 2023, Cureus, PMID:37842507). - Consanguinity increases risk in any AR disorder; not PEX6-specific but relevant to case ascertainment in the Mixteco and other founder clusters.

Protective factors: None specifically documented for PEX6-ZSD; general "protective" modifiers are hypomorphic (residual-function) missense alleles rather than null alleles — i.e., allelic severity itself is the modifying axis (genotype–phenotype correlation, §4), not an independent protective factor.

Gene–environment interactions: None established; this is a cell-autonomous biosynthetic/organelle-biogenesis defect not modulated by known exposures. (No CTD or GWAS-catalog environmental signal for PEX6-ZSD was found in this search; the disease is fully explained by the biallelic genetic lesion.)

Suggested terms: HP:0010984 (Digenic inheritance) is not applicable — PEX6-ZSD is monogenic AR, with the AEI mechanism being an unusual cis-regulatory dosage effect on a single locus rather than true digenic inheritance.

3. Phenotypes

Phenotype burden and severity track the ZSD continuum; PBD4B (PEX6, NALD/IRD-range) sits milder than classic Zellweger (PBD4A) but generally more severe than PEX1 p.Gly843Asp-type mild ZSD, though PEX6 alleles span an unusually broad range down to Heimler syndrome.

Quality-of-life impact: A dedicated caregiver-report QoL instrument for ZSD exists — "Proxy-Reported Symptoms and Quality of Life Survey in Zellweger Spectrum Disorders" (ClinicalTrials.gov NCT03440905) — but disease-specific EQ-5D/SF-36 published results were not surfaced in this search; QoL is dominated by combined sensory (hearing+vision) loss, motor/ataxia disability, and — where present — cognitive impairment and hepatic disease burden.

Severity/course as a class: A 2022 scoping review/meta-analysis, "Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings" (MDPI, Cells), formally stratifies ZSD severity by clinical-finding clusters and is a good source for quantitative frequency data across the whole ZSD population (PEX-gene-agnostic; PEX6 subgroup extractable).

4. Genetic/Molecular Information

Causal gene: PEX6 (HGNC:8858; NCBI Gene 5190; OMIM 601498), chromosome 6p21.1, 17 exons, encoding a AAA-ATPase family peroxin* with two tandem AAA-ATPase cassettes (Ebberink et al. 2010, PMID:19877282).

Variant landscape. A systematic screen of 75 PEX6-complementation-group patients identified 77 distinct mutations, 47 of them novel at the time, spanning missense, nonsense, frameshift, and splice-site classes (Ebberink et al. 2010, PMID:19877282: "Analysis of 75 patients assigned to the PEX6 complementation group revealed a total of 77 distinct mutations, with 47 being previously unreported and 14 representing polymorphic variants."). Loss-of-function alleles (nonsense/frameshift/large deletion) generally cluster with the severe (classic Zellweger, PBD4A) end; missense/hypomorphic alleles retaining partial function produce the PBD4B/NALD-IRD, SCAR3/SCABD, or Heimler-syndrome milder phenotypes (genotype–phenotype principle summarized in GeneReviews, NBK1448).

Notable specific variants: - c.2578C>T (p.Arg860Trp) — the unique monoallelic-sufficient PEX6 variant, pathogenic only when in cis with the 3′UTR AEI-driving variant rs144286892 (Falkenberg et al. 2017, Am J Hum Genet). This is a rare, mechanistically distinct example of dosage-driven "dominant" disease at a canonically AR peroxin locus. - c.1409G>C (p.Gly470Ala) — founder allele in the Mixteco population of Central California/Oaxaca-origin families, identified in 2 of 3 related neonatal PBD cases with severe (classic-range) presentation (Slaton et al. 2023, PMID:37842507). - A distinct French-Canadian founder PEX6 mutation elevates regional incidence in the Saguenay–Lac-Saint-Jean population of Quebec (PMC3483250).

Classification (ACMG/ClinVar): Multiple PEX6 variants are curated in ClinVar with pathogenic/likely-pathogenic classifications across "multiple conditions" (ZSD spectrum + Heimler syndrome), e.g., NM_000287.4(PEX6):c.2626C>T (p.Arg876Trp) reported for multiple conditions in ClinVar.

Population/allele frequency: Formal gnomAD-based carrier-frequency figures specific to PEX6 were not retrievable via this search pass (recommend a direct gnomAD v4 query for the curation step); one older ExAC data point noted a PEX6 c.1082G>A allele at ~0.41% in the European population (context/source secondary — verify directly before citing).

Somatic vs. germline: Germline only; PEX6-ZSD is not associated with somatic mosaicism reports in this search, though germline mosaicism cannot be excluded generically for an AR condition (no PEX6-specific report surfaced).

Functional consequence: Loss- or reduced-function of the PEX1/PEX6 AAA-ATPase heterohexameric motor (see Mechanism, §6) — impaired peroxisomal matrix-protein import, not a gain-of-function or dominant-negative mechanism in the classical biallelic-null cases; the AEI allele is a dosage/expression-level, not structural gain-of-function, mechanism.

Modifier genes: None specifically documented for PEX6 beyond the cis-acting 3′UTR AEI variant itself, which functions as its own allele-specific modifier.

Epigenetic/chromosomal information: No PEX6-specific DNA-methylation or chromosomal-rearrangement etiology was identified in this search; disease arises from coding/splice/UTR-regulatory sequence variants, not large chromosomal abnormalities.

Suggested gene/molecular terms: hgnc:8858 (PEX6); GO Molecular Function GO:0016887 (ATP hydrolysis activity) and GO:0043495 (protein-membrane adaptor activity, for the PEX1-PEX6-PEX26 anchoring complex) — verify exact GO ID via OAK before curation use.

5. Environmental Information

No environmental, lifestyle, or infectious contributing factors are described for PEX6-related PBD4B in the literature surveyed — it is a fully genetically determined organelle-biogenesis disorder. This section is not applicable beyond the population-genetic "environment" of founder effects in isolated/consanguineous communities (Mixteco, French-Canadian Saguenay–Lac-Saint-Jean) documented above, which are demographic/genetic rather than exposure-based risk factors.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Molecular lesion: Biallelic PEX6 pathogenic variants (or the monoallelic AEI mechanism) reduce/abolish functional PEX6 protein.
2. Complex disruption: PEX6 normally heterohexamerizes with PEX1 to form the peroxisomal receptor export module (REM), anchored to the peroxisomal membrane via PEX26 (mammalian ortholog of yeast Pex15/plant APEM9) (Nature Communications 2023, s41467-023-41640-9; PMC5762779; PMC9265785 review "Insights into the Structure and Function of the Pex1/Pex6 AAA-ATPase in Peroxisome Homeostasis"). "Pex1 and Pex6 form a heterohexameric motor essential for peroxisome biogenesis and function, and mutations in these AAA-ATPases cause most peroxisome-biogenesis disorders in humans."
3. Failure of PEX5 receptor recycling: The PTS1-import receptor PEX5, after delivering matrix (PTS1-tagged) enzymes into the peroxisomal lumen, is mono-ubiquitinated at a conserved cysteine and must be extracted back to the cytosol by the PEX1/PEX6 AAA-ATPase, which processively threads and unfolds ubiquitinated PEX5 through its central pore in an ATP-hydrolysis-dependent manner (PMC5762779, "The peroxisomal AAA-ATPase Pex1/Pex6 unfolds substrates by processive threading"). Loss of PEX6 function stalls this receptor-recycling/export step.
4. Peroxisomal matrix protein import failure: With PEX5 recycling blocked, both PTS1- and PTS2-mediated matrix protein import are impaired — demonstrated directly in PEX6-knockout cells by immunofluorescence, alongside a reduction in peroxisome number; overexpression of wild-type PEX6 restored import, confirming causality and highlighting a genetic-therapy rationale (search synthesis of PEX6 knockout/complementation studies).
5. Metabolic consequences (biochemical abnormalities): Failure to import peroxisomal beta-oxidation and ether-lipid-synthesis enzymes produces the ZSD biochemical signature: elevated very-long-chain fatty acids (VLCFA, C26:0/C26:1), decreased plasmalogens (C16/C18 erythrocyte membrane), elevated pipecolic acid, elevated C27 bile-acid intermediates (THCA/DHCA), and elevated C26:0-lysophosphatidylcholine (C26:0-LPC) on dried blood spot (GeneReviews NBK1448; JIMD 2017, PMID:28677031, sensitivity 89.2% for C26:0-LPC).
6. Downstream tissue injury:
7. Hepatotoxicity from accumulated C27 bile-acid intermediates (THCA/DHCA) — rationale for cholic-acid replacement therapy (§12).
8. Neural/white-matter injury from VLCFA/plasmalogen deficiency contributing to demyelination (leukodystrophy) and, in the SCAR3/SCABD presentation, cerebellar white-matter changes without atrophy plus demyelinating peripheral motor neuropathy (MONDO:0013931 definition).
9. Sensorineural hearing loss and retinal dystrophy, thought to reflect the combined effect of impaired ether-phospholipid (plasmalogen) content — essential in myelin and photoreceptor/cochlear membranes — and VLCFA accumulation.
10. Renal, skeletal (osteopenia), adrenal, and dental (amelogenesis imperfecta) involvement at the milder end of the spectrum.

Cell types/tissues implicated: hepatocytes, cochlear hair cells/spiral ganglion, retinal photoreceptors/RPE, cerebellar Purkinje neurons and oligodendrocytes (white matter), peripheral Schwann cells (demyelinating neuropathy), adrenal cortex, renal tubular epithelium, ameloblasts (dental enamel).

Zebrafish/mouse mechanistic model data (§15) reinforce this chain: zebrafish pex1/pex2 loss-of-function recapitulates "increased tissue levels of VLCFA and branched chain fatty acids as well as a reduction in ether phospholipids," with gene-expression changes in "crystallin (lens), troponin, parvalbumin (muscle contraction), and fatty acid metabolic genes," directly linking the biochemical lesion to the cataract/lens and myopathic phenotypic themes seen clinically.

Suggested GO Biological Process terms (verify via OAK before use): GO:0016558 (protein import into peroxisome matrix), GO:0007031 (peroxisome organization), GO:0006635 (fatty acid beta-oxidation), GO:0008611 (ether lipid biosynthetic process / plasmalogen synthesis). Suggested CL terms: CL:0000182 (hepatocyte), CL:0000540 (neuron; refine to Purkinje cell / photoreceptor / cochlear hair cell as appropriate), CL:0002573 (Schwann cell), CL:0000064 (ciliated columnar cell — not applicable, remove) — refine per node.

7. Anatomical Structures Affected

Organ level (primary): liver, central nervous system (cerebrum white matter, cerebellum), peripheral nervous system, inner ear (cochlea), eye (retina, lens), adrenal gland, kidney, skeleton, teeth. Body systems: hepatobiliary, nervous (central and peripheral), special sensory (audiovestibular, visual), endocrine (adrenal), renal, skeletal, dental/craniofacial. Tissue/cell level: hepatocytes and biliary epithelium; cerebellar cortex (Purkinje cells) and cerebral/cerebellar white matter (oligodendrocytes/myelin); peripheral motor nerve myelin (Schwann cells); cochlear hair cells and spiral ganglion neurons; retinal photoreceptors and RPE; lens epithelium (cataract); adrenal cortical cells; renal tubular epithelium; ameloblasts/odontoblasts (enamel/dentin). Subcellular level: the peroxisome itself (matrix and membrane), with GO Cellular Component anchors GO:0005777 (peroxisome), GO:0005778 (peroxisomal membrane); secondary organelle stress in mitochondria (shared fission machinery/metabolic crosstalk) is plausible but not directly documented in this search. Localization/laterality: bilateral/symmetric in essentially all reported manifestations (symmetric leukodystrophy on MRI per PMID:25079577; bilateral sensorineural hearing loss; bilateral retinal dystrophy) — consistent with a systemic, non-lateralized metabolic mechanism.

Suggested UBERON terms (verify before use): UBERON:0002107 (liver), UBERON:0002037 (cerebellum), UBERON:0001851 (cortex), UBERON:0001846 (cochlea... verify exact ID), UBERON:0000970 (eye), UBERON:0000029 (lymph node — not relevant, omit), UBERON:0002369 (adrenal gland), UBERON:0002113 (kidney).

8. Temporal Development

Onset: Ranges continuously across the PEX6 allelic series: - Neonatal (severe/classic end, PBD4A): hypotonia, dysmorphism, seizures at birth. - Infantile (NALD/IRD-type, PBD4B core): developmental delay, hepatic and sensory (hearing/vision) involvement emerging in infancy–early childhood. - Later childhood/school-age (SCAR3/SCABD presentation): can present first as an isolated finding on a school hearing screen at age 6.5–7 years, with ataxia and leukodystrophy following (PMID:25079577). - Very mild/Heimler end: hearing loss + dental enamel defects recognized in childhood, sometimes with only late or subtle retinal findings.

Onset pattern: insidious/progressive in the milder forms; acute-appearing decompensation (diplopia, coordination loss, cognitive decline) can punctuate an otherwise stable course, as in the PMID:25079577 case ("acute-onset diplopia, coordination difficulties, and cognitive decline at age 7" after years of normal development).

Progression / disease course pattern: predominantly progressive (leukodystrophy, sensorineural loss, hepatic fibrosis, osteopenia) but with a subgroup showing a non-progressive, stable course after an initial insult — GeneReviews notes "children who survive the first year and who have a non-progressive course have a 77% probability of reaching school age." Course is therefore bimodal: progressive-demyelinating (worse prognosis) vs. stable/non-progressive (better prognosis).

Duration: classic/severe end is typically fatal in infancy ("usually die during the first year of life"); milder NALD/IRD/SCAR3/Heimler-range disease is chronic and lifelong, with IRD-range patients reported reaching adulthood.

Remission: Not applicable — this is a fixed genetic enzymatic/organelle defect without spontaneous remission; "remission" concepts apply only to individual complications (e.g., seizure control) via symptomatic treatment.

Critical periods: Neonatal/early-infantile window is critical for diagnosis (newborn-screening C26:0-LPC assays) and initiation of nutritional/hepatic supportive care before irreversible white-matter or hepatic injury accrues; there is no known disease-modifying intervention that alters the peroxisomal defect itself once diagnosed (§12).

9. Inheritance and Population

Inheritance pattern: Autosomal recessive (biallelic PEX6 pathogenic variants), with the well-documented exception of the p.Arg860Trp allelic-expression-imbalance mechanism, which produces disease from a single (over-expressed) mutant allele in cis with a specific 3′UTR variant (Falkenberg et al. 2017) — described by GeneReviews as "One PEX6 variant, p.Arg860Trp, has been associated with ZSD in the heterozygous state due to allelic expression imbalance dependent on allelic background." Asymptomatic parents heterozygous for the same coding variant but lacking the 3′UTR AEI variant do not manifest disease, confirming the cis-regulatory (not simple dominant) mechanism.

Penetrance: Effectively complete for biallelic null/severe genotypes; variable expressivity governs the resulting phenotype (severe vs. milder ZSD vs. Heimler) rather than penetrance per se.

Expressivity: Markedly variable, correlating with residual peroxisomal-import function — this is the central genotype–phenotype axis for PEX6, spanning classic Zellweger through NALD/IRD, SCAR3/SCABD, and Heimler syndrome from different combinations of PEX6 alleles.

Genetic anticipation: Not applicable/not reported (not a repeat-expansion disorder).

Germline mosaicism: Not specifically reported for PEX6 in this search.

Founder effects: - French-Canadian (Saguenay–Lac-Saint-Jean, Quebec) founder PEX6 mutation, associated with regional ZSD incidence approaching ~1/12,000 vs. ~1/50,000 North American baseline (PMC3483250). - Mixteco population (Central California, Oaxaca-origin) founder variant c.1409G>C (p.Gly470Ala), identified in a 2023 cluster of 3 related neonatal cases (Slaton et al., PMID:37842507), with authors recommending targeted community screening/awareness.

Consanguinity: Relevant risk-amplifier in founder/isolated populations (implied in both founder reports) though not separately quantified in this search.

Carrier frequency: Formal PEX6-specific gnomAD carrier-frequency figures were not directly retrieved in this pass (recommend direct gnomAD v4 lookup for curation); general ZSD (all-PEX-gene) carrier frequency is consistent with the ~1/50,000–1/100,000 birth-incidence estimates below.

Epidemiology (birth prevalence/incidence, whole-ZSD, PEX-gene-agnostic since PEX6-specific figures are not separately tabulated): - North America/US: ~1/50,000 births (classic estimate); newborn-screening-based C26:0-LPC data from New York gave 1:133,000 births (GeneReviews) — the discrepancy is attributed to biochemical assays underestimating mild/atypical ZSD. - Quebec (Saguenay–Lac-Saint-Jean), Canada: highest reported regional incidence, ~1/12,000, driven by the PEX6 founder allele. - Japan: ~1/500,000, reflecting absence of the common European PEX1 founder alleles (p.Ile700Tyrfs42, p.Gly843Asp); PEX6 relative contribution in Japan not separately reported here. - Within ZSD, PEX6 accounts for ~10–14.5%* of genetically solved cases (second only to PEX1's ~60%) (GeneReviews NBK1448; Ebberink et al. 2010).

Sex ratio: No sex bias reported (autosomal recessive; consistent with equal male:female representation in described cohorts, e.g., the Mixteco case series and the late-onset PEX6 case being male — anecdotal, not indicative of a true sex bias).

Geographic/ethnic distribution: Elevated in French-Canadian (Saguenay–Lac-Saint-Jean) and Mixteco (Central California/Oaxaca) founder populations specifically for PEX6; broader ZSD (all genes) shows the North-America-vs.-Japan contrast above driven mainly by PEX1 founder-allele presence/absence.

10. Diagnostics

Biochemical screening (first-line): - Plasma VLCFA (C26:0, C26:1; ratios) — elevated; caution re: false positives in non-fasting samples. - Erythrocyte membrane plasmalogens (C16, C18) — decreased; may be normal in mild disease. - Plasma/urine pipecolic acid — elevated (urine more sensitive in neonates, plasma in older children). - Plasma/urine C27 bile-acid intermediates (THCA, DHCA) — elevated. - C26:0-lysophosphatidylcholine (C26:0-LPC) on dried blood spot — newborn-screening-compatible marker; sensitivity 89.2% (86/91 DBS samples, 33/37 patients) in a dedicated evaluation study (JIMD 2017, PMID:28677031). GeneReviews explicitly cautions: "Some individuals with ZSD do not have abnormalities of these screening assays," mandating molecular confirmation for atypical/mild cases.

Genetic testing (confirmatory, required for diagnosis per GeneReviews): - Multigene PEX panel (13 known PEX genes) is the preferred first-tier molecular test for a suggestive phenotype. - Exome/genome sequencing for atypical presentations (e.g., isolated hearing loss/ataxia without classic biochemical signature, as in the Usher-mimic and late-onset leukodystrophy cases). - Single-gene PEX6 testing is not generally recommended as a first step (panel/exome preferred), per GeneReviews sequence-detection-rate table (PEX6 ~100% detection rate, 77/77 alleles, once the complementation group is known).

Other modalities: - Brain MRI: symmetric leukodystrophy (white-matter change, non-enhancing) in the milder/late-onset presentations; cerebellar white-matter change without atrophy in the SCAR3/SCABD presentation. - Audiology: baseline and annual sensorineural hearing loss assessment. - Ophthalmology: annual assessment for retinal dystrophy/pigmentary retinopathy and cataract. - Liver panel / imaging: LFTs, coagulation factors, hepatic ultrasound/fibroscan for fibrosis surveillance. - Fibroblast complementation/functional studies: historically used to assign PEX6 complementation group and confirm impaired PTS1/PTS2 import (as in the original PEX6-defective family report, PMID:11873320). - Dental exam: enamel/dentin abnormality assessment, especially relevant at the Heimler end.

Differential diagnosis: - Other PEX-gene ZSD (PEX1 especially — clinically indistinguishable without molecular testing). - X-linked adrenoleukodystrophy (X-ALD, ABCD1) — elevated VLCFA but normal other peroxisomal markers; explicitly the key differential in the late-onset PEX6 case (PMID:25079577), where ABCD1 sequencing/dosage was normal, prompting the correct PEX6 diagnosis. - D-bifunctional protein deficiency, acyl-CoA oxidase deficiency (single peroxisomal enzyme defects mimicking ZSD biochemically) — GeneReviews notes ~15% of ZSD-like/VLCFA-elevated cases are actually single-enzyme defects. - Usher syndrome — the PEX6 "Usher-syndrome mimic" phenomenon (deafness + retinitis pigmentosa) led to a negative Usher panel before compound-heterozygous PEX6 variants were found in a 12-year-old boy (ScienceDirect/PMC PEX6-Usher-mimic report). - Other syndromic hearing-loss/retinal-dystrophy conditions; other leukodystrophies and hypotonia syndromes (myotonic dystrophy, SMA, Prader-Willi) at the neonatal-severe end.

Screening: Newborn screening for ZSD via C26:0-LPC on dried blood spot is implemented in some US states/programs (e.g., 9 California NBS-positive infants 2016–2022, 7 confirmed ZSD by biallelic PEX-gene variants); carrier/targeted screening is recommended in the Mixteco founder population per Slaton et al. 2023.

Suggested LOINC/marker anchors for curation: VLCFA panel, plasmalogen assay, pipecolic acid, THCA/DHCA, C26:0-LPC — verify specific LOINC codes at curation time.

11. Outcome/Prognosis

Severe end (classic Zellweger, PBD4A-range PEX6 genotypes): poor prognosis; "usually die during the first year of life, usually having made no developmental progress," typically from progressive apnea or respiratory infection (GeneReviews NBK1448).

Milder end (PBD4B/NALD-IRD, SCAR3/SCABD, Heimler): - Survivors past year one with a non-progressive course have a 77% probability of reaching school age (GeneReviews). - A subset develops progressive demyelinating leukodystrophy, causing skill loss and eventually death — the key prognostic bifurcation within the milder group. - Progressive sensory deficits (hearing, vision) are common even in stable/non-progressive courses. - Some individuals retain normal intellectual function. - Adults are rarely diagnosed (historically under-recognized) and typically present with predominantly sensory (hearing/vision) deficits and otherwise normal neurologic development — consistent with the IRD/SCAR3-type adult survivors.

Complications driving morbidity: hepatic fibrosis/failure and esophageal varices, adrenal insufficiency, osteopenia/fracture risk, renal oxalate stones, combined sensory (dual hearing-vision) impairment, seizures.

Prognostic factors: genotype (null/severe vs. hypomorphic/missense allele combination — the dominant driver, §4/§9), progressive vs. non-progressive leukoencephalopathy course, age at diagnosis/intervention, degree of residual peroxisomal import function.

Formal severity-stratification resource: the 2022 MDPI Cells scoping review/meta-analysis/chart review on "Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings" is a good source for quantitative clinical-finding-based severity/prognostic staging across ZSD (verify PMID/exact figures directly for curation-grade quotes).

12. Treatment

There is no disease-modifying/curative therapy for the underlying peroxisomal defect; management is symptomatic/supportive, organized around annual multisystem surveillance (GeneReviews NBK1448):

Cholic-acid pharmacotherapy detail: rationale is suppression of hepatotoxic C27 bile-acid intermediate (THCA/DHCA) synthesis via restored feedback inhibition. A 19-patient open-label pretest–posttest trial (9 months) found cholic acid "can suppress bile acid synthesis in ZSD patients and, thereby, decrease plasma levels of toxic C27-bile acid intermediates. However, no effect on clinically relevant outcome measures could be observed after 9 months of CA treatment" (Cholic acid therapy in ZSD, PMC5065608 / PMID:27469511), with an important safety caveat that cholic acid can worsen liver disease in individuals with pre-existing fibrosis/advanced liver disease — necessitating careful patient selection. Long-term case reports (Karger Case Reports in Gastroenterology, PMC6062720) describe extended cholic-acid treatment courses.

Experimental/investigational: No PEX6-specific gene therapy, ASO, or targeted molecular therapy in active late-stage development was identified in this search; a US patent ("Compositions and methods for the treatment of Zellweger spectrum disorder," USPTO 11065247) indicates active IP/early-stage interest but no confirmed clinical-trial-stage disease-modifying agent. The PEX6-overexpression rescue of matrix-protein import in PEX6-knockout cells (fibroblast complementation data, §6) provides in vitro proof-of-concept for a gene-supplementation therapeutic strategy, but this remains preclinical.

Ongoing trials: NCT03440905 (Proxy-Reported Symptoms and Quality of Life Survey in ZSD) is a natural-history/outcomes-measure study rather than an interventional trial — useful for future trial-readiness and outcome-measure development, not itself a treatment.

Treatment strategy: Management follows an annual/biannual multidisciplinary surveillance algorithm (audiology, ophthalmology, hepatology labs+imaging, adrenal function, urine oxalate, dental exam every 6 months post-secondary-dentition eruption, head MRI as needed for new neurologic decline, growth/nutrition and developmental monitoring at every visit) rather than a linear treatment algorithm, since no curative option exists (GeneReviews NBK1448).

13. Prevention

Primary prevention: Not applicable in the classic sense (monogenic disorder, no modifiable environmental cause); the closest analog is carrier screening and genetic counseling in at-risk/founder populations.

Secondary prevention (early detection): - Newborn screening via C26:0-LPC dried-blood-spot assay is implemented in some jurisdictions and enables presymptomatic identification and earlier supportive-care initiation. - Targeted community screening recommended for the Mixteco population given the identified c.1409G>C founder allele (Slaton et al. 2023).

Genetic counseling / reproductive options: - Standard AR recurrence-risk counseling: 25% recurrence risk per pregnancy for carrier couples. - Carrier screening, preimplantation genetic diagnosis, and prenatal testing are appropriate once a familial PEX6 genotype is known — standard GTR/ACMG-consistent recommendations for a well-characterized AR gene; no PEX6-specific prenatal-screening program beyond general peroxisomal-disorder prenatal biochemical/molecular testing was identified in this search. - In founder populations (French-Canadian Saguenay–Lac-Saint-Jean, Mixteco), population-targeted carrier screening is the most actionable, evidence-supported prevention lever documented.

Tertiary prevention: the entire supportive-care/surveillance regimen in §12 functions as tertiary prevention (preventing/mitigating complications — hepatic decompensation, fracture, renal stone complications, missed sensory-loss-related developmental impact) in individuals already diagnosed.

Immunization: Annual influenza and RSV vaccination per standard pediatric schedules is explicitly recommended as part of ZSD management (GeneReviews) to reduce respiratory-infection mortality risk, particularly relevant given respiratory infection is a leading proximate cause of death in severe ZSD.

14. Other Species / Natural Disease

No naturally occurring PEX6-associated disease in companion animals or wildlife (OMIA-type veterinary entity) was identified in this search — peroxisome biogenesis disorders are not documented as a recognized spontaneous veterinary disease class for PEX6 specifically. PEX6 is broadly conserved across vertebrates (ortholog present in mouse, zebrafish — see §15) and lower eukaryotes (yeast Pex6p performs the analogous AAA-ATPase/Pex15p-anchored receptor-export function, underscoring deep evolutionary conservation of the PEX1/PEX6/PEX26(Pex15) module described in §6). No zoonotic or transmission relevance — this is a non-infectious inherited metabolic/organelle-biogenesis disorder.

15. Model Organisms

Mouse: - Murine Pex6 (MGI:2385054) knockout/complementation studies show, consistent with human pathophysiology: fewer peroxisomes, impaired PTS1/PTS2-mediated matrix protein import (immunofluorescence-confirmed), and rescue of import upon PEX6 overexpression — supporting a gene-supplementation therapeutic rationale (search-synthesized from PEX6-knockout literature; IMPC/MGI hold the formal allele/phenotype records). - Related PEX1 mouse models (e.g., the PEX1-p.Gly844Asp knock-in) have been used to study RPE structural/lipid changes relevant to the retinal phenotype in milder ZSD (bioRxiv 2024.09.05.611330) — directly informative for the PEX6-associated retinal dystrophy phenotype by extension of the shared PEX1/PEX6 complex biology. - Classic Pex1-null and other Pex-null mice are frequently early embryonic/perinatal lethal, limiting study of postnatal disease progression — a key model limitation relative to human milder ZSD.

Zebrafish (increasingly favored for peroxisomal-disorder modeling because postnatal lethality is circumvented): - pex2 zebrafish mutants: locomotive defects, feeding disability, liver abnormalities, early death — recapitulating classic-ZSD-like severity (Takashima et al. 2021, cited in "Modelling Peroxisomal Disorders in Zebrafish," PMC11764017/MDPI 2073-4409/14/2/147). - pex1 loss-of-function zebrafish: viable (unlike mouse), enabling study of ZSD pathophysiology beyond early development; recapitulates hallmark biochemical features — increased VLCFA and branched-chain fatty acids, reduced ether phospholipids (plasmalogens) — plus organ-specific fatty-acid-species accumulation and broad transcriptomic changes including reduced crystallin (lens), troponin, and parvalbumin (muscle) gene expression (bioRxiv 2021.01.03.425169; Frontiers in Molecular Neuroscience 2025, "Pex1 loss-of-function in zebrafish is viable and recapitulates hallmarks of Zellweger spectrum disorders"). - No PEX6-specific zebrafish line was identified by name in this search, but given the shared PEX1/PEX6 heterohexameric complex mechanism, the pex1 zebrafish model is considered broadly informative for PEX6-mediated disease and is the most translationally active current small-vertebrate ZSD model.

Cellular models: Patient-derived fibroblasts are the primary human cellular model, used historically to assign PEX6 complementation-group status and to demonstrate the PEX6-overexpression rescue of peroxisomal import described above — directly bridging molecular mechanism (§6) to therapeutic hypothesis-generation.

Model limitations (general, applicable to PEX6-ZSD): mouse null models are often too severe/lethal to model the milder NALD/IRD/SCAR3/Heimler end of the human PEX6 allelic spectrum; zebrafish, while viable and biochemically faithful, differ from humans in CNS complexity (limiting direct modeling of the cerebellar ataxia/leukodystrophy phenotype) and audiovestibular/retinal anatomy (limiting precise recapitulation of the sensorineural-hearing-loss and retinal-dystrophy phenotypes that dominate the milder PEX6 clinical picture) — a human-model-mismatch consideration worth flagging explicitly if this is curated into a dismech HUMAN_MODEL_MISMATCH discussion node, particularly for the SCAR3/SCABD ataxia-deafness-blindness presentation, which has not yet been shown to be faithfully reproduced in any existing PEX6 animal model in the literature surveyed.

Key PMIDs / Citations Compiled

Data gaps flagged for curation: (1) precise gnomAD v4 PEX6 carrier-frequency figures — needs direct database query; (2) quantitative phenotype-frequency percentages specific to the PEX6 subgroup (vs. all-ZSD) — the 2022 Cells severity-characterization meta-analysis is the best lead; (3) confirmation of whether any PEX6-specific (as opposed to pan-PEX1/pan-ZSD) animal model exists in current MGI/ZFIN records; (4) exact current OMIM clinical-synopsis field values for #614863 (OMIM.org blocked direct fetch in this session — recommend direct OMIM API/manual lookup before finalizing a KB entry).

Sources: - Entry - #614863 - PEROXISOME BIOGENESIS DISORDER 4B; PBD4B - OMIM - Entry - #614862 - PEROXISOME BIOGENESIS DISORDER 4A (ZELLWEGER); PBD4A - OMIM - Entry - *601498 - PEROXISOME BIOGENESIS FACTOR 6; PEX6 - OMIM - Zellweger Spectrum Disorder - GeneReviews - NCBI Bookshelf (NBK1448) - Spectrum of PEX6 mutations in Zellweger syndrome spectrum patients - PubMed (PMID:19877282) - Late-onset Zellweger spectrum disorder caused by PEX6 mutations mimicking X-linked adrenoleukodystrophy - PubMed (PMID:25079577) - Zellweger's Syndrome With PEX6 Gene Mutation in Mixteco Neonates Due to Possible Founder Effect - PMC (PMID:37842507) - A founder mutation in the PEX6 gene is responsible for increased incidence of Zellweger syndrome in a French Canadian population - PMC - Allelic Expression Imbalance Promoting a Mutant PEX6 Allele Causes Zellweger Spectrum Disorder - Cell.com AJHG - PEX6 Mutations in Peroxisomal Biogenesis Disorders: An Usher Syndrome Mimic - ScienceDirect - Heimler Syndrome Is Caused by Hypomorphic Mutations in the Peroxisome-Biogenesis Genes PEX1 and PEX6 - PMC - Spectrum of PEX1 and PEX6 variants in Heimler syndrome - EJHG - Structure of the peroxisomal Pex1/Pex6 ATPase complex bound to a substrate - Nature Communications - The peroxisomal AAA-ATPase Pex1/Pex6 unfolds substrates by processive threading - PMC - Insights into the Structure and Function of the Pex1/Pex6 AAA-ATPase in Peroxisome Homeostasis - PMC - Peroxisomal monoubiquitinated PEX5 interacts with the AAA ATPases PEX1 and PEX6 - ScienceDirect - Evaluation of C26:0-lysophosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders - PubMed - Cholic acid therapy in Zellweger spectrum disorders - PMC - Long-Term Cholic Acid Therapy in Zellweger Spectrum Disorders - PMC - Braverman et al., Peroxisome biogenesis disorders in the Zellweger spectrum overview - Mol Genet Metab (PMID:26750748) - Zellweger spectrum disorders: clinical overview and management approach - PubMed/Orphanet J Rare Dis - Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings - MDPI Cells - Modelling Peroxisomal Disorders in Zebrafish - PMC - Pex1 loss-of-function in zebrafish is viable and recapitulates hallmarks of Zellweger spectrum disorders - Frontiers - Zebrafish model of human Zellweger syndrome reveals organ specific accumulation of distinct fatty acid species - bioRxiv - Pex6 MGI Mouse Gene Detail - MGI:2385054 - peroxisome biogenesis disorder 4B MONDO:0013931 - Monarch Initiative - Peroxisome biogenesis disorder 4B - NIH Genetic Testing Registry (GTR) - Orphanet: PEX6-peroxisomal biogenesis factor 6 - Orphanet: Infantile Refsum disease - Orphanet: Neonatal adrenoleukodystrophy - Proxy-Reported Symptoms and Quality of Life Survey in Zellweger Spectrum Disorders - ClinicalTrials.gov NCT03440905

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Peroxisome Biogenesis Disorder 4B
• MONDO ID: MONDO:0013931,PEX6-related,OMIM:614863,also-called-SCAR3/SCABD1,non-classic-Zellweger-spectrum (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Peroxisome Biogenesis Disorder 4B covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Peroxisome Biogenesis Disorder 4B: comprehensive disease-characteristics report

Executive summary and entity-resolution warning

Peroxisome biogenesis disorder 4B (PBD4B) is an autosomal-recessive, PEX6-related Zellweger-spectrum disorder (ZSD). Residual PEX6 activity produces a continuum from childhood/adult neurologic disease to the very mild Heimler syndrome 2 phenotype; near-complete loss of function produces severe neonatal Zellweger disease. Open Targets maps MONDO:0013931 specifically to PEX6 (Ensembl ENSG00000124587) with a disease–target score of 0.809. (OpenTargets Search: peroxisome biogenesis disorder 4B-PEX6)

The supplied synonym string requires correction. “SCAR3/SCABD1” is not supported as a synonym of PEX6-related PBD4B in the retrieved disease-gene or clinical evidence and should not be loaded as an exact synonym. “Non-classic Zellweger-spectrum disorder,” “mild PEX6-related ZSD,” and “Heimler syndrome 2” are appropriate overlapping labels, although Heimler syndrome describes the mild sensory-dental end of the spectrum rather than every PBD4B patient. (OpenTargets Search: peroxisome biogenesis disorder 4B-PEX6, munozpujol2022diagnosticodysseyin pages 1-2)

The following table provides a compact curation summary; details and qualifications follow.

Table: This table condenses high-confidence knowledge-base facts for PEX6-related peroxisome biogenesis disorder 4B, separating PEX6-specific findings from broader Zellweger spectrum evidence. It is useful for rapid curation of nomenclature, phenotypes, diagnostics, mechanism, prognosis, treatment status, and model-system evidence.

1. Disease information

Definition

PBD4B is a congenital disorder of peroxisome assembly caused by biallelic pathogenic variants in PEX6. The resulting deficiency affects multiple peroxisomal pathways rather than one enzyme. ZSD is therefore a clinical and biochemical continuum: severe neonatal disease includes profound hypotonia, seizures, feeding and respiratory failure, liver dysfunction, sensory impairment and dysmorphism; attenuated disease may present with hearing loss, retinal dystrophy, enamel abnormalities, ataxia, neuropathy or leukodystrophy in childhood or adulthood. The mildest recognized presentation, Heimler syndrome, is dominated by sensorineural hearing loss, amelogenesis imperfecta and retinal dystrophy. (munozpujol2022diagnosticodysseyin pages 1-2, ahangari2026unravelingpex6insights pages 2-3)

A useful published definition is: “Peroxisomal biogenesis disorders (PBDs) are a heterogeneous group of genetic diseases. Multiple peroxisomal pathways are impaired.” The same report emphasizes that presentation ranges from “severe, lethal multisystemic disorders to milder, late-onset disease.” (munozpujol2022diagnosticodysseyin pages 1-2)

Identifiers and names

• MONDO: MONDO:0013931, peroxisome biogenesis disorder 4B.
• OMIM: 614863 is the supplied and conventionally used PBD4B identifier; severe PEX6-related PBD4A is separately represented as OMIM 614862. The phenotypes are allelic and clinically continuous.
• Gene: PEX6, peroxisomal biogenesis factor 6; Ensembl ENSG00000124587. (OpenTargets Search: peroxisome biogenesis disorder 4B-PEX6)
• MeSH: Zellweger syndrome, D015211; Peroxisome Biogenesis Disorders, C536664, as represented in ClinicalTrials.gov indexing. (NCT03856866 chunk 1)
• Orphanet: ZSD is generally indexed at spectrum level; a PBD4B-specific Orphanet identifier was not verified in the retrieved material.
• ICD-10/ICD-11: no uniquely verified PBD4B code was found. Coding generally falls under disorders of peroxisomal function/other specified metabolic disorders; local terminology should be checked before database ingestion.
• Supported synonyms: PEX6-related peroxisome biogenesis disorder; PEX6-related Zellweger-spectrum disorder; mild/non-classic ZSD due to PEX6; Heimler syndrome 2 for the mild sensory-dental phenotype.
• Not an exact synonym: SCAR3/SCABD1.

Evidence in this report is primarily aggregated disease-level literature and registries, supplemented by individual case reports and small cohorts. It is not derived from an EHR population.

2. Etiology

Causal factor

The cause is germline biallelic pathogenic PEX6 variation. PEX6 encodes an AAA-family ATPase that complexes with PEX1 and is anchored by PEX26. The complex extracts ubiquitinated PEX5 from the peroxisomal membrane after delivery of PTS1-containing matrix proteins. Loss of this activity disrupts matrix-protein import and peroxisome quality control. (biase2020laboratorydiagnosisof pages 1-2, law2017theperoxisomalaaa pages 1-6)

Genetic risk and genotype–phenotype relationship

• Two pathogenic alleles are ordinarily required. Null/truncating alleles or severely disruptive missense alleles tend toward neonatal disease; hypomorphic missense/splice alleles retaining activity tend toward PBD4B, Heimler-like or adult-onset disease. This is a tendency, not a deterministic rule. (ahangari2026unravelingpex6insights pages 2-3, ahangari2026unravelingpex6insights pages 1-2)
• A 2023 PEX6-specific series identified homozygous NM_000287.4:c.1409G>C, p.(Gly470Ala) in three Mixteco neonates with severe ZSD. All had hypotonia, liver abnormalities and marked VLCFA abnormalities; two were known to die by approximately three to six months. (slaton2023zellweger’ssyndromewith pages 3-4, slaton2023zellweger’ssyndromewith pages 2-3, slaton2023zellweger’ssyndromewith pages 1-2)
• A reported homozygous c.1992G>C, p.(Glu664Asp) case had developmental delay, dysmorphism and hearing loss despite normal plasma VLCFAs, illustrating that genotype can be more informative than a single biochemical screen. (ahangari2026unravelingpex6insights pages 2-3, ahangari2026unravelingpex6insights pages 3-5)
• PEX6 can also phenocopy Perrault syndrome, with hearing loss and ovarian dysfunction/neurologic disease. Genomic work identified PEX6 variants including p.(Leu124Pro) and p.(Arg786Trp), broadening ascertainment beyond classic ZSD. (tucker2020genomicsequencinghighlights pages 1-7)

Variant interpretation should use ClinVar/ACMG evidence at the exact transcript and genome build. No comprehensive, current PEX6 ClinVar export or variant-level gnomAD frequencies was retrieved, so individual population frequencies and classifications should not be inferred here.

Environmental, protective and gene–environment factors

No toxin, infection, smoking, alcohol, occupation or lifestyle exposure is established as a primary cause. Sex is not a causal risk factor. Consanguinity and founder structure increase the probability that two carriers reproduce but do not alter the molecular mechanism. The Mixteco clustering suggests a founder effect, but three cases are insufficient to establish a population carrier frequency. (slaton2023zellweger’ssyndromewith pages 1-2)

No validated protective PEX6 allele, environmental protective factor or reproducible PEX6-specific modifier gene is known from the retrieved evidence. Nutrition and avoidance of prolonged fasting may reduce secondary metabolic stress but do not prevent the genetic disease. Temperature-sensitive residual import has been demonstrated for some other AAA-complex defects; it is mechanistically interesting but not an established clinical gene–environment intervention.

3. Phenotypes

Phenotype frequencies are poorly quantified for PEX6-PBD4B because published cohorts combine genes and severity classes. The values below are therefore qualitative unless a PEX6-specific denominator is given.

In the three-infant series, C26:0 was 7.17–8.27 µmol/L versus a stated reference of 0.17–0.73; C26/C22 was 0.424–0.592 versus 0.003–0.015. Phytanic and pristanic acids were normal in all three, showing that not every pathway marker is abnormal at every age. (slaton2023zellweger’ssyndromewith pages 2-3)

Formal patient-level EQ-5D, SF-36 or PROMIS estimates were not found. A completed caregiver study, NCT03440905, enrolled 92 caregivers and measured communication, medical care, emotional distress, role function, family interaction, parenting and disability-related support using PIP and FQOL instruments. This confirms substantial multidomain family burden, although retrieved registry text did not provide outcome scores. (NCT03440905 chunk 1)

4. Genetic and molecular information

Gene and protein

• Gene: PEX6; peroxisomal biogenesis factor 6.
• Protein class: type-II AAA ATPase/peroxin.
• Cellular location/function: cytosolic/peroxisome-associated PEX1–PEX6 complex, recruited by PEX26, which uses ATP to recycle PEX5.
• Origin: germline; somatic PEX6 mutations are not the mechanism of Mendelian PBD4B.
• Functional consequence: predominantly loss of function or partial loss of function. No established gain-of-function or dominant-negative PBD4B mechanism was identified.

Variant classes include missense, nonsense, frameshift, canonical and deep-intronic splice variants, and potentially exon-level deletions/duplications. A negative sequencing test should therefore prompt assessment of copy-number and splice-altering variants when biochemical or clinical suspicion remains high.

Variant examples

• c.1409G>C, p.Gly470Ala: severe homozygous neonatal phenotype in three Mixteco infants; described as pathogenic in the clinical report. (slaton2023zellweger’ssyndromewith pages 3-4, slaton2023zellweger’ssyndromewith pages 1-2)
• c.1992G>C, p.Glu664Asp: homozygous PEX6-related ZSD with normal plasma VLCFA in a reported child. (ahangari2026unravelingpex6insights pages 2-3)
• p.Leu124Pro and p.Arg786Trp: identified in genomic analysis of a Perrault-like PEX6 phenotype; the supplementary evidence documents phase/haplotype work. (tucker2020genomicsequencinghighlights pages 1-7)

Population allele frequencies were not available in the retrieved full text. Database curation should record a frequency only after direct gnomAD/TOPMed query on the correct transcript/build.

Modifiers, epigenetics and chromosome abnormalities

No validated modifier gene, disease-specific methylation signature, histone alteration or recurrent chromosomal rearrangement was identified. Large deletions encompassing PEX6 are theoretically detectable by copy-number analysis, but PBD4B is principally a sequence-level recessive disorder. Karyotype, FISH and methylation testing are not first-line tests.

5. Environmental information

Environmental toxins, radiation, pollution, smoking, alcohol and infectious agents do not cause PBD4B. Intercurrent infection, fasting, malnutrition and drug toxicity can worsen an affected person's clinical state, especially liver, respiratory or adrenal instability, but these are stressors/complications, not etiologic factors. Influenza A with bacterial pneumonia and recurrent pneumonia contributed to deterioration in one severely affected infant. (slaton2023zellweger’ssyndromewith pages 3-4)

There is no zoonotic, transmissible or infectious component. Standard vaccination, infection prevention and adequate nutrition are applicable supportive measures, not disease-specific prevention.

6. Mechanism and pathophysiology

Upstream causal chain

1. Biallelic PEX6 loss/hypomorphism reduces ATP-dependent activity of the PEX1–PEX6–PEX26 AAA complex.
2. PEX5 recycling fails. PEX5 normally binds PTS1-tagged cargo, docks at PEX13/PEX14, releases cargo, becomes ubiquitinated and is extracted back into cytosol by the AAA complex. (biase2020laboratorydiagnosisof pages 1-2, law2017theperoxisomalaaa pages 1-6)
3. Ubiquitinated PEX5 accumulates on the membrane, matrix-protein import becomes inefficient, and residual empty membrane structures—“peroxisomal ghosts”—predominate.
4. Ubiquitinated PEX5 can recruit selective autophagy machinery, increasing pexophagy and reducing functional peroxisome abundance. Law et al. stated: “The loss of AAA-complex function in cells results in the accumulation of ubiquitinated PEX5 on the peroxisomal membrane that signals pexophagy.” (law2017theperoxisomalaaa pages 1-6)
5. Multiple metabolic pathways fail simultaneously: VLCFA β-oxidation; phytanic-acid α-oxidation; C27 bile-acid-intermediate shortening; DHA synthesis; ether-phospholipid/plasmalogen synthesis; pipecolate oxidation; and peroxisomal redox control. ACMG emphasizes plasma VLCFA/branched-chain fatty acids and erythrocyte plasmalogens because they sample these defects. (biase2020laboratorydiagnosisof pages 1-2)
6. Downstream tissue injury reflects toxic substrate accumulation, membrane-lipid deficiency, altered bile acids, oxidative stress and secondary mitochondrial/ER dysfunction. Vulnerable systems include developing brain and white matter, retina, cochlea, hepatocytes, adrenal cortex, kidney and skeletal/dental tissues.

Suggested ontology annotations

• GO biological process: protein import into peroxisome matrix; peroxisomal transport; very-long-chain fatty-acid catabolic process; fatty-acid beta-oxidation; ether-lipid biosynthetic process; bile-acid biosynthetic process; reactive-oxygen-species metabolic process; autophagy of peroxisome/pexophagy.
• GO cellular component: peroxisome (GO:0005777), peroxisomal membrane, peroxisomal matrix, PEX1–PEX6 ATPase complex.
• Cell Ontology candidates: hepatocyte (CL:0000182), neuron (CL:0000540), oligodendrocyte (CL:0000128), retinal photoreceptor cell (CL:0000210), retinal pigment epithelial cell, cochlear hair cell, adrenal cortical cell, renal tubular epithelial cell, fibroblast (CL:0000057).
• CHEBI candidates: hexacosanoic acid/C26:0; phytanic acid; pristanic acid; plasmalogens; dihydroxycholestanoic acid; trihydroxycholestanoic acid; docosahexaenoic acid; cholic acid; hydrogen peroxide.

Immune, omics and advanced technology evidence

Immune activation is probably secondary to tissue stress rather than a primary autoimmune or immunodeficiency mechanism. No PEX6-specific human single-cell, spatial-transcriptomic, epigenomic or integrated multi-omics dataset was retrieved. Current molecular profiling is dominated by targeted metabolite/lipid measurements and cell-based import assays. Thus, claims about specific inflammatory cell populations or epigenetic drivers would be premature.

7. Anatomical structures affected

Primary organ systems: central and peripheral nervous systems; eye/retina; inner ear/cochlea; liver and biliary system; adrenal gland; kidney; skeleton and teeth. Secondary involvement includes respiratory muscle/airway function, nutrition/gastrointestinal feeding, cardiac congenital anomalies and reproductive function in Perrault-like presentations. (ahangari2026unravelingpex6insights pages 2-3, slaton2023zellweger’ssyndromewith pages 3-4)

Suggested anatomical terms include UBERON:0000955 brain, UBERON:0002316 white matter, UBERON:0000966 retina, cochlea/inner ear, UBERON:0002107 liver, adrenal gland, kidney, peripheral nerve, tooth enamel and skeletal muscle. Disease is generally bilateral/systemic; unilateral localization is not characteristic. Retinal and auditory disease are commonly bilateral.

At subcellular resolution, the primary compartment is the peroxisome, especially its membrane import/export machinery and matrix. Secondary organelle effects involve mitochondria, ER and lysosome/autophagosome pathways.

8. Temporal development

Three broad courses are recognized:

1. Neonatal–infantile severe ZSD: congenital dysmorphism, profound hypotonia, low Apgar scores, feeding/respiratory failure, liver dysfunction and sensory abnormalities. Progression is rapid, with death often during the first year. The 2023 series states that neonatal presentations “typically have a life expectancy of less than one year.” (slaton2023zellweger’ssyndromewith pages 1-2)
2. Childhood attenuated ZSD/PBD4B: developmental impairment, hearing/visual loss, liver/adrenal abnormalities, neuropathy and evolving white-matter disease. Course is chronic and variably progressive.
3. Adolescent/adult or Heimler-like disease: hearing loss, enamel defects and retinal dystrophy may dominate; ataxia, neuropathy or leukodystrophy can emerge later. Mild cases may have normal first-line biochemical tests and long diagnostic delays. (munozpujol2022diagnosticodysseyin pages 1-2, ahangari2026unravelingpex6insights pages 2-3)

There is no established spontaneous remission. Early diagnosis is important for hearing/vision support, nutrition, adrenal surveillance, family planning and avoidance of diagnostic delay, but no proven developmental window for curative therapy exists.

9. Inheritance and population

Inheritance is autosomal recessive. When both parents are confirmed heterozygotes, each pregnancy has a 25% affected, 50% carrier and 25% non-carrier probability. Penetrance for two truly pathogenic severe alleles is expected to be high, but expressivity is markedly variable because residual function differs. Anticipation is not expected. Germline mosaicism is theoretically possible but not a recognized major mechanism.

The ZSD birth incidence quoted in the 2023 clinical report is approximately 1 in 50,000 US newborns, but this is pan-ZSD, not PEX6-PBD4B prevalence. No reliable PEX6-specific incidence, prevalence, sex ratio or carrier frequency was found. Both sexes are affected. (slaton2023zellweger’ssyndromewith pages 1-2)

Possible population effects include:

• Mixteco: three homozygous p.Gly470Ala infants born at one Central California hospital; the authors proposed a founder mutation but explicitly called for larger, culturally inclusive study. (slaton2023zellweger’ssyndromewith pages 1-2)
• A French-Canadian PEX6 founder mutation was cited by the Mixteco report, but exact carrier/incidence estimates were not available in retrieved text. (slaton2023zellweger’ssyndromewith pages 6-6)
• Consanguinity increases recessive disease risk but was denied in one Mixteco family and unknown in two, so it cannot explain that cluster by itself. (slaton2023zellweger’ssyndromewith pages 1-2)

10. Diagnostics

Biochemical testing

The ACMG technical standard recommends a coordinated biochemical and molecular approach. First-line biochemical investigations include:

• plasma VLCFAs: C26:0 concentration and C24/C22, C26/C22 ratios;
• plasma phytanic and pristanic acids;
• erythrocyte plasmalogens;
• plasma/urine C27 bile-acid intermediates;
• pipecolic acid where available;
• liver enzymes, bilirubin, coagulation, adrenal function and renal studies according to presentation. (biase2020laboratorydiagnosisof pages 1-2)

The standard states: “The current diagnostic approach relies heavily on biochemical genetic tests measuring peroxisomal metabolites, including very long-chain and branched-chain fatty acids in plasma and plasmalogens in red blood cells.” (biase2020laboratorydiagnosisof pages 1-2)

Normal VLCFAs do not exclude mild PEX6 disease. Where phenotype suggests Heimler syndrome, retinal-hearing disease or unexplained ataxia/leukodystrophy, molecular testing plus broader metabolomics—such as C26:0-lysophosphatidylcholine and bile-acid species—is appropriate. (ahangari2026unravelingpex6insights pages 2-3, ahangari2026unravelingpex6insights pages 3-5)

Clinical and functional testing

Recommended phenotyping includes newborn/diagnostic ABR and serial audiology; ophthalmologic examination, fundus photography, OCT, ERG and visual fields; brain MRI for neuronal migration defects or leukodystrophy; liver ultrasound/elastography as indicated; EEG for seizures; nerve-conduction studies/EMG for neuropathy; developmental assessment; dental examination; and morning cortisol/ACTH testing where adrenal disease is possible. HARP used ERG voltage, OCT, visual acuity, plasmalogens, phytanic acid and C26/C22 as measurable endpoints. (NCT03856866 chunk 1)

Molecular testing strategy

1. Use a peroxisomal-disorder/ZSD multigene panel that includes PEX6 and deletion/duplication analysis, or WES/WGS when presentation is broad.
2. Confirm candidate variants and parental phase by Sanger/segregation analysis.
3. If only one allele is identified, examine CNVs, intronic/splice variants and consider RNA sequencing in fibroblasts or blood when informative.
4. Pair sequencing with biochemical evaluation to establish the extent of peroxisome dysfunction and help classify VUS. ACMG notes that molecular testing commonly uses a multigene panel or exome/genome approach and that metabolic evaluation remains important when NGS is first tier. (biase2020laboratorydiagnosisof pages 1-2)

CMA may detect a large deletion but is low-yield for typical PBD4B. Karyotyping, FISH, mtDNA testing and repeat-expansion testing are not routine. RNA-seq is an adjunct for suspected splice defects; proteomics, epigenomics and liquid biopsy are not established diagnostics.

Differential diagnosis

Important alternatives include other PEX-gene ZSDs; single-enzyme peroxisomal disorders such as D-bifunctional protein deficiency and ACOX1 deficiency; X-linked adrenoleukodystrophy; rhizomelic chondrodysplasia punctata; Usher syndrome and other deaf-blindness syndromes; isolated amelogenesis imperfecta with hearing loss; Perrault syndrome genes; mitochondrial disease; congenital disorders of glycosylation; lysosomal disease; and hereditary ataxia/leukodystrophy. Distinguishing features are a multi-pathway peroxisomal biochemical signature and biallelic PEX6 variants.

Screening

PEX6-PBD4B is not a universal stand-alone newborn-screening target. C26:0-lysophosphatidylcholine screening used for X-ALD may incidentally identify some severe peroxisomal disorders, but mild PEX6 cases can be biochemically normal. Cascade carrier testing is recommended after a familial genotype is known. Prenatal diagnosis and PGT-M are feasible using known familial variants.

11. Outcome and prognosis

There are no robust PEX6-specific 5- or 10-year survival curves. Prognosis is driven principally by residual peroxisomal function and neonatal severity.

• Severe neonatal disease has high infant mortality. In the three p.Gly470Ala cases, one male died at approximately three months and one female at about six months; the third was placed on comfort care, with subsequent survival not established in the report. (slaton2023zellweger’ssyndromewith pages 3-4, slaton2023zellweger’ssyndromewith pages 1-2)
• Mild patients can survive into adulthood but may experience progressive hearing loss, retinal degeneration, ataxia, neuropathy, adrenal disease and leukodystrophy. (munozpujol2022diagnosticodysseyin pages 1-2, ahangari2026unravelingpex6insights pages 2-3)
• Major morbidity arises from deafness/blindness, motor and cognitive disability, seizures, feeding dependence, liver disease and respiratory infections.

Adverse prognostic indicators include neonatal onset, profound hypotonia, seizures, severe liver/coagulation disease, major feeding/respiratory compromise, markedly defective import and two null/severe alleles. Residual biochemical function and hypomorphic missense alleles generally predict longer survival, but individual prediction remains imprecise.

12. Treatment

Current standard

There is no curative or proven PEX6-specific disease-modifying therapy. Management is multidisciplinary and symptom-directed:

• nutrition assessment, caloric support, feeding therapy, aspiration management and gastrostomy when necessary;
• seizure treatment using standard antiseizure medicines selected with attention to liver function;
• hearing aids/cochlear implantation and communication support;
• low-vision services, refraction, retinal monitoring and treatment of actionable ocular complications;
• physical, occupational, speech and developmental therapy;
• liver, coagulation, renal and adrenal monitoring, with hormone replacement for confirmed adrenal insufficiency;
• dental prevention/restoration for enamel disease;
• respiratory support, infection treatment, sleep/airway evaluation and palliative care for severe neonatal disease.

Suggested MAXO concepts include genetic counseling, molecular genetic testing, biochemical testing, hearing assessment, hearing-aid fitting, cochlear implantation, ophthalmologic examination, retinal imaging, physical therapy, occupational therapy, speech therapy, gastrostomy, enteral nutrition, seizure management, adrenal surveillance and palliative care.

Pharmacologic and experimental interventions

Cholic acid. This can suppress synthesis of hepatotoxic C27 bile-acid intermediates in selected ZSD patients with bile-acid abnormalities/liver disease. Evidence is pan-ZSD and does not establish neurologic or PEX6-specific efficacy. Liver disease can progress despite treatment, so it is not curative.

Hydroxychloroquine/pexophagy inhibition. HARP, NCT03856866, was a completed randomized, quadruple-masked, placebo-controlled crossover series of N-of-1 trials. It enrolled 3 participants with PEX1-, PEX6- or PEX26-related PBD, using hydroxychloroquine 4 mg/kg/day for 84 days, an 84-day washout and crossover; endpoints included ERG, plasmalogens, phytanic acid and C26/C22. No genotype-stratified peer-reviewed clinical benefit was retrieved. (NCT03856866 chunk 1) Moreover, a 2021 cellular study found that chloroquine, hydroxychloroquine and 3-methyladenine did not restore function and could worsen matrix import/metabolism. Its conclusion was: “Our results do not support the use of autophagy inhibitors as potential treatment for PBD-ZSD patients.” This was primarily PEX1-G843D cellular evidence, but it argues against off-label HCQ for PEX6 outside research. (klouwer2021autophagyinhibitorsdo pages 1-2)

Betaine. NCT01838941 was an open-label, single-group six-month trial in 12 participants, but eligibility was restricted to PEX1-G843D genotypes. It is therefore not evidence for PEX6-PBD4B. Doses were 6 g/day below 30 kg and 12 g/day above 30 kg. (NCT01838941 chunk 1)

L-arginine and molecular chaperones. L-arginine improved functions in some PEX1-G843D cells and remains preclinical; applicability to PEX6 is unproven. (klouwer2021autophagyinhibitorsdo pages 1-2)

Gene/RNA/cell therapy. No approved PEX6 gene replacement, CRISPR, ASO, siRNA or cell therapy was identified. Major challenges include multisystem delivery, treatment before developmental injury and appropriate control of PEX6 expression/complex assembly.

Current studies and real-world infrastructure

• NCT01668186: recruiting longitudinal PBD natural-history study, planned enrollment 244, with annual clinical, biochemical, MRI and retinal assessments. (NCT01668186 chunk 1)
• NCT06190626: recruiting ZSD retinopathy natural-history study, enrollment 30.
• NCT03440905: completed caregiver symptom/QoL survey, enrollment 92. (NCT03440905 chunk 1)
• NCT03115086: active-not-recruiting Cholbam/cholic-acid registry, enrollment 55.

No established PEX6 pharmacogenomic dosing guideline was found.

13. Prevention

Primary lifestyle prevention is not possible after conception because disease is caused by inherited PEX6 variants. Effective genetic prevention options are:

• preconception and prenatal genetic counseling;
• targeted carrier testing for relatives and potentially founder populations after the founder association is validated;
• partner testing;
• IVF with PGT-M;
• chorionic-villus sampling or amniocentesis for known familial variants;
• donor gametes or adoption according to family preferences.

Secondary prevention means early recognition through biochemical and genetic diagnosis, especially when hearing loss, enamel defects and retinal dystrophy coexist. Tertiary prevention includes vaccination, aspiration and infection prevention, nutrition, hearing/vision intervention, seizure control, adrenal-crisis education and surveillance of liver/renal disease. No vaccine, prophylactic drug or environmental intervention prevents the underlying PEX6 defect.

14. Other species and naturally occurring disease

PEX6 and the PEX1–PEX6 recycling mechanism are evolutionarily conserved across eukaryotes. Relevant taxa include Homo sapiens (NCBI Taxon 9606), Mus musculus (10090), Danio rerio (7955), Drosophila melanogaster (7227) and budding yeast. Orthologous Pex6 participates in ATP-dependent receptor recycling.

No well-established, naturally occurring companion-animal or livestock PEX6 syndrome with validated breed/VBO annotation was found in the retrieved evidence. Therefore, a specific veterinary breed association, cross-species transmission or zoonotic potential should be recorded as not established/not applicable. PBD4B is inherited, not infectious.

15. Model organisms and experimental systems

Patient cells

Cultured skin fibroblasts are the most directly relevant model. Assays include catalase or PTS1 immunofluorescence, matrix-protein import, temperature rescue, VLCFA oxidation, plasmalogen synthesis and complementation. AAA-complex cellular models show ubiquitinated PEX5 accumulation and pexophagy. Law et al. reported rescue of peroxisome number/import/function after autophagy inhibition, whereas later work in four PEX1-G843D cell types found metabolic worsening with pharmacologic autophagy inhibitors, illustrating model- and genotype-dependence. (klouwer2021autophagyinhibitorsdo pages 1-2, law2017theperoxisomalaaa pages 1-6)

Mouse

Global severe peroxisome-biogenesis knockouts reproduce hypotonia, neuronal migration abnormalities, liver disease and early lethality, limiting longitudinal postnatal experiments. Hypomorphic PEX1 models reproduce attenuated ZSD liver/metabolic disease and are useful for therapy development, but they are not exact PEX6-PBD4B models. Conditional neural, hepatic or glial Pex knockouts help identify tissue-specific mechanisms.

Zebrafish

Zebrafish peroxisome-deficiency models permit live developmental imaging, locomotor and retinal phenotyping, lipid analysis and drug screening. They can reproduce VLCFA/branched-chain lipid accumulation, defective import, visual abnormalities and stress/pexophagy signatures. Most retrieved models were Pex1 or other peroxins rather than Pex6, so translation to PBD4B is mechanistically relevant but indirect.

Drosophila and yeast

Drosophila peroxin mutants reproduce reduced lifespan, locomotor abnormalities, retinal/neural degeneration, lipid dysregulation and infertility. Yeast remains a powerful structural and functional system for Pex1/Pex6 ATPase assembly, Pex5 export and variant complementation. Limitations include divergent organ physiology, lipid pathways and developmental phenotypes.

Evidence gaps and research priorities

1. A PEX6-specific longitudinal cohort with standardized HPO frequencies, survival and genotype-residual-function data.
2. Direct ClinVar/gnomAD curation of all reported PEX6 alleles, including founder haplotypes.
3. Human retinal, cochlear, neural and hepatic cell models—preferably isogenic iPSC/organoid systems.
4. PEX6 knock-in animal models for common severe and hypomorphic alleles.
5. Biomarkers sensitive to mild disease when VLCFAs are normal.
6. Controlled testing of gene replacement, allele-specific rescue or safe modulation of peroxisome quality control.

Selected authoritative sources and dates

• Slaton D et al. “Zellweger’s Syndrome With PEX6 Gene Mutation in Mixteco Neonates Due to Possible Founder Effect.” Published 13 September 2023. DOI/URL: https://doi.org/10.7759/cureus.45162. PEX6-specific human case series. (slaton2023zellweger’ssyndromewith pages 1-2)
• De Biase I et al. ACMG technical standard for laboratory diagnosis of peroxisomal disorders. Approved 15 October 2019; published 2020. DOI/URL: https://doi.org/10.1038/s41436-019-0713-9. (biase2020laboratorydiagnosisof pages 1-2)
• Law KB et al. “The peroxisomal AAA ATPase complex prevents pexophagy and development of peroxisome biogenesis disorders.” 2017. DOI/URL: https://doi.org/10.1080/15548627.2017.1291470. Primary cell-mechanism study. (law2017theperoxisomalaaa pages 1-6)
• Klouwer FCC et al. “Autophagy Inhibitors Do Not Restore Peroxisomal Functions…” Published 1 April 2021. DOI/URL: https://doi.org/10.3389/fcell.2021.661298. Primary in-vitro study. (klouwer2021autophagyinhibitorsdo pages 1-2)
• Muñoz-Pujol G et al. Adult mild ZSD diagnosis using WES/RNA-seq. Published October 2022. DOI/URL: https://doi.org/10.3390/ijms232012367. Although PEX1-specific, it supports diagnostic principles for mild PEX6 disease. (munozpujol2022diagnosticodysseyin pages 1-2)
• Braverman NE et al. Current diagnosis, manifestations and treatment guidelines. PMID 26750748; DOI: 10.1016/j.ymgme.2015.12.009. Listed as authoritative background for the ZSD QoL trial. (NCT03440905 chunk 1)
• HARP hydroxychloroquine trial, NCT03856866: https://clinicaltrials.gov/study/NCT03856866. (NCT03856866 chunk 1)
• PBD natural-history study, NCT01668186: https://clinicaltrials.gov/study/NCT01668186. (NCT01668186 chunk 1)
• ZSD caregiver QoL study, NCT03440905: https://clinicaltrials.gov/study/NCT03440905. (NCT03440905 chunk 1)

Overall evidence assessment: the causal PEX6–PBD4B relationship and core peroxisomal-import mechanism are strong. Phenotype breadth is well established, but PEX6-specific frequencies, population prevalence, long-term survival, modifier genes and treatment-response estimates remain limited. Most therapeutic and natural-history evidence is pan-ZSD or PEX1-dominant and should not be represented as proven PEX6-specific efficacy.

References

1. (OpenTargets Search: peroxisome biogenesis disorder 4B-PEX6): Open Targets Query (peroxisome biogenesis disorder 4B-PEX6, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (munozpujol2022diagnosticodysseyin pages 1-2): Gerard Muñoz-Pujol, Socorro Alforja-Castiella, Ricardo Casaroli-Marano, Blai Morales-Romero, Judit García-Villoria, Vicente A. Yépez, Julien Gagneur, Mirjana Gusic, Holger Prokisch, Frederic Tort, and Antonia Ribes. Diagnostic odyssey in an adult patient with ophthalmologic abnormalities and hearing loss: contribution of rna-seq to the diagnosis of a pex1 deficiency. International Journal of Molecular Sciences, 23:12367, Oct 2022. URL: https://doi.org/10.3390/ijms232012367, doi:10.3390/ijms232012367. This article has 7 citations.

3. (slaton2023zellweger’ssyndromewith pages 1-2): Daniel Slaton, Ashley Chang, Tamanna Ahluwalia, Sophie Alfaro, Britani Javed, and Rocky Greer. Zellweger’s syndrome with pex6 gene mutation in mixteco neonates due to possible founder effect. Cureus, Sep 2023. URL: https://doi.org/10.7759/cureus.45162, doi:10.7759/cureus.45162. This article has 1 citations.

4. (ahangari2026unravelingpex6insights pages 2-3): Najmeh Ahangari, Bita Barazandeh Shirvan, Farah Ashrafzadeh, Ehsan Ghayoor Karimiani, Narges Hashemi, Shima Imannezhad, Hashem Lashgari Kalat, Farnoosh Ebrahimzadeh, Javad Akhondian, and Mehran Beiraghi Toosi. Unraveling pex6: insights into very-long-chain fatty acid levels and peroxisome biogenesis disorders in pediatric populations. Annals of Pediatric Endocrinology & Metabolism, 31:3-10, Feb 2026. URL: https://doi.org/10.6065/apem.2550134.067, doi:10.6065/apem.2550134.067. This article has 1 citations.

5. (biase2020laboratorydiagnosisof pages 1-2): Irene De Biase, Silvia Tortorelli, Lisa Kratz, Steven J. Steinberg, Kristina Cusmano-Ozog, and Nancy Braverman. Laboratory diagnosis of disorders of peroxisomal biogenesis and function: a technical standard of the american college of medical genetics and genomics (acmg). Genetics in Medicine, 22:686-697, Apr 2020. URL: https://doi.org/10.1038/s41436-019-0713-9, doi:10.1038/s41436-019-0713-9. This article has 29 citations and is from a highest quality peer-reviewed journal.

6. (slaton2023zellweger’ssyndromewith pages 3-4): Daniel Slaton, Ashley Chang, Tamanna Ahluwalia, Sophie Alfaro, Britani Javed, and Rocky Greer. Zellweger’s syndrome with pex6 gene mutation in mixteco neonates due to possible founder effect. Cureus, Sep 2023. URL: https://doi.org/10.7759/cureus.45162, doi:10.7759/cureus.45162. This article has 1 citations.

7. (slaton2023zellweger’ssyndromewith pages 2-3): Daniel Slaton, Ashley Chang, Tamanna Ahluwalia, Sophie Alfaro, Britani Javed, and Rocky Greer. Zellweger’s syndrome with pex6 gene mutation in mixteco neonates due to possible founder effect. Cureus, Sep 2023. URL: https://doi.org/10.7759/cureus.45162, doi:10.7759/cureus.45162. This article has 1 citations.

8. (klouwer2021autophagyinhibitorsdo pages 1-2): Femke C. C. Klouwer, Kim D. Falkenberg, Rob Ofman, Janet Koster, Démi van Gent, Sacha Ferdinandusse, Ronald J. A. Wanders, and Hans R. Waterham. Autophagy inhibitors do not restore peroxisomal functions in cells with the most common peroxisome biogenesis defect. Frontiers in Cell and Developmental Biology, Apr 2021. URL: https://doi.org/10.3389/fcell.2021.661298, doi:10.3389/fcell.2021.661298. This article has 23 citations.

9. (NCT03856866 chunk 1): Neal Sondheimer. Hydroxychloroquine Administration for Reduction of Pexophagy. The Hospital for Sick Children. 2019. ClinicalTrials.gov Identifier: NCT03856866

10. (ahangari2026unravelingpex6insights pages 3-5): Najmeh Ahangari, Bita Barazandeh Shirvan, Farah Ashrafzadeh, Ehsan Ghayoor Karimiani, Narges Hashemi, Shima Imannezhad, Hashem Lashgari Kalat, Farnoosh Ebrahimzadeh, Javad Akhondian, and Mehran Beiraghi Toosi. Unraveling pex6: insights into very-long-chain fatty acid levels and peroxisome biogenesis disorders in pediatric populations. Annals of Pediatric Endocrinology & Metabolism, 31:3-10, Feb 2026. URL: https://doi.org/10.6065/apem.2550134.067, doi:10.6065/apem.2550134.067. This article has 1 citations.

11. (ahangari2026unravelingpex6insights pages 1-2): Najmeh Ahangari, Bita Barazandeh Shirvan, Farah Ashrafzadeh, Ehsan Ghayoor Karimiani, Narges Hashemi, Shima Imannezhad, Hashem Lashgari Kalat, Farnoosh Ebrahimzadeh, Javad Akhondian, and Mehran Beiraghi Toosi. Unraveling pex6: insights into very-long-chain fatty acid levels and peroxisome biogenesis disorders in pediatric populations. Annals of Pediatric Endocrinology & Metabolism, 31:3-10, Feb 2026. URL: https://doi.org/10.6065/apem.2550134.067, doi:10.6065/apem.2550134.067. This article has 1 citations.

12. (law2017theperoxisomalaaa pages 1-6): Kelsey B. Law, Dana Bronte-Tinkew, Erminia Di Pietro, Ann Snowden, Richard O. Jones, Ann Moser, John H. Brumell, Nancy Braverman, and Peter K. Kim. The peroxisomal aaa atpase complex prevents pexophagy and development of peroxisome biogenesis disorders. Autophagy, 13:868-884, May 2017. URL: https://doi.org/10.1080/15548627.2017.1291470, doi:10.1080/15548627.2017.1291470. This article has 134 citations and is from a domain leading peer-reviewed journal.

13. (slaton2023zellweger’ssyndromewith pages 6-6): Daniel Slaton, Ashley Chang, Tamanna Ahluwalia, Sophie Alfaro, Britani Javed, and Rocky Greer. Zellweger’s syndrome with pex6 gene mutation in mixteco neonates due to possible founder effect. Cureus, Sep 2023. URL: https://doi.org/10.7759/cureus.45162, doi:10.7759/cureus.45162. This article has 1 citations.

14. (NCT03440905 chunk 1): Proxy-Reported Symptoms and Quality of Life Survey in Zellweger Spectrum Disorders. University of South Florida. 2018. ClinicalTrials.gov Identifier: NCT03440905

15. (NCT01668186 chunk 1): Nancy Braverman. Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD). McGill University Health Centre/Research Institute of the McGill University Health Centre. 2012. ClinicalTrials.gov Identifier: NCT01668186

16. (tucker2020genomicsequencinghighlights pages 1-7): Elena J. Tucker, Rocio Rius, Sylvie Jaillard, Katrina Bell, Phillipa J. Lamont, André Travessa, Juliette Dupont, Lurdes Sampaio, Jérôme Dulon, Sandrine Vuillaumier-Barrot, Sandra Whalen, Arnaud Isapof, Tanya Stojkovic, Susana Quijano-Roy, Gorjana Robevska, Jocelyn van den Bergen, Chloe Hanna, Andrea Simpson, Katie Ayers, David R. Thorburn, John Christodoulou, Philippe Touraine, and Andrew H. Sinclair. Genomic sequencing highlights the diverse molecular causes of perrault syndrome: a peroxisomal disorder (pex6), metabolic disorders (clpp, ggps1), and mtdna maintenance/translation disorders (lars2, tfam). Human Genetics, 139:1325-1343, May 2020. URL: https://doi.org/10.1007/s00439-020-02176-w, doi:10.1007/s00439-020-02176-w. This article has 48 citations and is from a peer-reviewed journal.

17. (NCT01838941 chunk 1): Nancy Braverman. Betaine and Peroxisome Biogenesis Disorders. McGill University Health Centre/Research Institute of the McGill University Health Centre. 2013. ClinicalTrials.gov Identifier: NCT01838941

Artifacts

• Edison artifact artifact-00